98%
921
2 minutes
20
In Southern U.S. states with high HIV incidence and low HIV Pre-Exposure Prophylaxis (PrEP) uptake, enhanced efforts to increase interest in and willingness to use PrEP are needed. This implementation survey examined the associations of sociodemographic background, substance use, and sexual risk behaviors with willingness to use daily oral and long-acting injectable (LAI) PrEP among substance using men who have sex with men (SU-MSM). Participants were 225 SU-MSM recruited from sexually transmitted infection (STI) clinics, syringe services programs (SSPs), and substance use treatment programs (SUTPs) in eight Southern U.S. cities. Rates of willingness were high for both daily oral PrEP (78%) and LAI PrEP (66%). In multivariable analyses, distinct factors were associated with willingness towards each. For daily oral PrEP, greater willingness was associated with condomless anal sex, less frequent non-injection opioid use, prior PrEP awareness, and past use of PrEP. For LAI PrEP, greater willingness was associated with Black race, identifying as gay, being single, and higher injection drug use frequency. Lower willingness to use LAI PrEP was associated with higher non-injection opioid use frequency. Findings about willingness to use LAI PrEP, as a relatively newer modality, and greater willingness among Black SU-MSM as a disproportionately HIV-impacted population, are especially important. These findings argue for the necessity to enhance PrEP promotion efforts that distinguish between oral and LAI PrEP and that are specifically tailored to major SU-MSM subgroups in the Southern U.S.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10461-024-04594-7 | DOI Listing |
PLoS One
September 2025
Departments of Epidemiology and Global Health, University of Washington, School of Public Health, Seattle, Washington, United States of America.
Background: Long-acting injectable pre-exposure prophylaxis (LAI-PrEP) for HIV prevention may improve adherence for those with concerns with daily pills. Limited data exist on LAI-PrEP acceptability among Black women in the U.S.
View Article and Find Full Text PDFAIDS Res Ther
August 2025
The Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Background: Long-acting injectable (LAI)-PrEP provides better protection against HIV compared to oral PrEP, which requires taking a daily pill. Our study aimed to assess knowledge about oral and LAI-PrEP and identify factors associated with willingness to use LAI-PrEP among key populations (KPs) in Uganda.
Methods: We conducted a cross-sectional study at the Most at Risk Populations Initiative (MARPI) clinic between November and December 2021.
J Acquir Immune Defic Syndr
August 2025
Department of Work and Social Psychology, Maastricht University, Maastricht, the Netherlands.
Background: Long-acting injectable pre-exposure-prophylaxis (LAI-PrEP) offers potentials for expanding PrEP coverage and improving public health outcomes. This study synthesises evidence on the prevalence and determinants of interest in and preference for LAI-PrEP among men-who-have-sex-with-men (MSM), trans* individuals, and heterosexual women.
Methods: We conducted this systematic review and meta-analysis building on quantitative studies from a previous review and new studies published in PubMed, Web of Science, and Embase up to December 31, 2023.
AIDS Behav
August 2025
Behavioral Health Equity Program, Department of Psychiatry, Boston Medical Center, Boston, MA, USA.
People with opioid use disorder (PWOUD) are at high risk of HIV infection, yet uptake of PrEP remains low in PWOUD. To understand opportunities to increase PrEP engagement, this cross-sectional study sought to examine clinical correlates of perceived PrEP use likelihood in a sample of PWOUD along the OUD Treatment Cascade. We enrolled 120 PWOUD with past-6-month injection drug use (IDU) or condomless sex in a cross-sectional survey study.
View Article and Find Full Text PDFJ Antimicrob Chemother
August 2025
Department of Internal Medicine, Hospital Universitario Infanta Leonor, Madrid, Spain.
Long-acting injectable cabotegravir plus rilpivirine (LAI CAB + RPV) represents an important advance in HIV treatment, offering an alternative to daily oral antiretroviral therapy (ART) for people with HIV (PWH) who are virologically suppressed. This narrative review aims to (i) evaluate the effectiveness and safety of LAI CAB + RPV in real-world clinical practice; (ii) assess outcomes in key subgroups, including women, older adults, people with elevated BMI, transgender people, and those with adherence challenges; and (iii) discuss practical and implementation considerations relevant to routine care. We synthesized the most up-to-date evidence from peer-reviewed publications and major international HIV conferences.
View Article and Find Full Text PDF